CUSTOM DEVICE SOLUTIONS – Device Design Will Act as Competitive Distinguisher in a Post-Patent Expiry Biosimilar Market

Boasting over 15,000 readers, Drug Development and Delivery is published nine times a year to offer its subscribers the latest information on drug Research & Development. Committed to advancing the applied science, technology, and related business practices of pharmaceutical and biological drug development, Drug Development & Delivery provides pharmaceutical professionals with practical solutions to the issues, opportunities, and challenges in the ever-evolving drug development communities.

The biosimilars landscape is rapidly evolving; we’ve seen a vast number of original reference biologics reach expiry for patent exclusivity – 15 in the US during the 2018-2023 period alone – and the market opportunity for biosimilar manufacturers expand in parallel.

As some of the world’s best-known biologics continue to reach patent expiration, the approval and uptake of biosimilars is expected to pick up even more over the coming years.